rosuvastatin + fidaxomicin
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-Drug Interaction (DDI)
Conditions
Drug-Drug Interaction (DDI), Intestinal Absorption, Healthy Subjects, Pharmacokinetics of Rosuvastatin, Pharmacokinetics of Fidaxomicin
Trial Timeline
Feb 1, 2013 → Mar 1, 2013
NCT ID
NCT02083627About rosuvastatin + fidaxomicin
rosuvastatin + fidaxomicin is a phase 1 stage product being developed by Astellas Pharma for Drug-Drug Interaction (DDI). The current trial status is completed. This product is registered under clinical trial identifier NCT02083627. Target conditions include Drug-Drug Interaction (DDI), Intestinal Absorption, Healthy Subjects.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02083627 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-Drug Interaction (DDI)